Table 2. Clinical and cardiovascular outcomes in patient with KD

	Younger age (n = 168)	Usual age (n = 407)	Older age (n = 69)
Incomplete KD (%)	103 (61.3)1)2)	172 (42.3)	29 (42.0)
Recurrence (%)	3 (1.8)	30 (7.3)1)	9 (13.0)2)
IVIG resistance (%)	36 (21.6)	110 (27.0)	21 (30.4)
Steroid pulse therapy as second treatment (%)	6 (16.7)	31 (29.0)	4 (23.5)
Coronary artery dilatation at acute phase (%)	21 (12.5)	43 (10.6)	4 (5.8)
Giant coronary aneurysm at acute phase (%)	0	0	2 (2.9)2)3)
Coronary artery dilatation at 2 mon follow-up (%)	2 (1.2)	7 (1.7)	1 (1.4)
Giant coronary aneurysm at 2 mon follow-up (%)	0	0	1 (1.4)
Mitral regurgitation (%)	44 (26.5)	149 (36.9)1)	18 (26.5)
Pericardial effusion (%)	12 (7.2)	38 (9.4)	7 (10.3)

Data are shown as number (%).
Younger age: ≤ 12 mon; Usual age: 13–60 mon; older age: > 60 mon.
P < 0.05, compared with the younger and usual age group.
P < 0.05, compared with the younger age and older age group.
P < 0.05, compared with the usual age and older age group.
KD: Kawasaki disease; IVIG: intravenous immunoglobulin.